Status:
UNKNOWN
Dose Enhancement of Vancomycin IN Everyday Patients
Lead Sponsor:
The Canberra Hospital
Conditions:
Vancomycin Therapy
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
Current Australian guidelines for vancomycin commonly underdoses individuals particularly in the first 48 hours. The aim of the trial is to compare two dosing regimens; the current Australian guideli...
Detailed Description
DEVINE will be a randomised controlled trial of a new vancomycin dosing regimen against a control. The control group regimen will receive the doses recommended by Therapeutic Guidelines - Antibiotics...
Eligibility Criteria
Inclusion
- All patients in general wards requiring routine treatment with vancomycin
Exclusion
- GFR \< 30mL/min(as measured by Cockcroft Gault equation)
- Age \< 16 yrs
- Weight \> 200kg
- Patients dosing with Vancomycin other than BD according to national guidelines (ie continuous infusions, q6h etc)
- Vancomycin infused at a rate other than 500mL/min
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01427842
Start Date
August 1 2011
End Date
July 1 2012
Last Update
September 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Canberra Hospital
Canberra, Australian Capital Territory, Australia, 2605